T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Zentalis Pharmaceuticals
ZNTL
$307M
| $249M | 0.02% |
3,730,425
+470,857
| +14% | +$27.2M |
|
477
Banco Santander Chile
BSAC
$16B
| $246M | 0.02% |
12,464,221
+603,385
| +5% | +$11.9M |
|
478
PennyMac Financial
PFSI
$4B
| $244M | 0.02% |
3,998,944
-55,225
| -1% | -$3.51M |
|
479
Lennox International
LII
$14.5B
| $244M | 0.02% |
830,855
-237,717
| -22% | -$77.6M |
|
480
Infosys
INFY
$49.7B
| $244M | 0.02% |
10,977,347
-479,289
| -4% | -$10.8M |
|
481
Colgate-Palmolive
CL
$73.6B
| $244M | 0.02% |
3,229,075
-29,757
| -0.9% | -$2.36M |
|
482
Motorola Solutions
MSI
$77.7B
| $244M | 0.02% |
1,049,098
+107,862
| +11% | +$25M |
|
483
Rexford Industrial Realty
REXR
$8.11B
| $240M | 0.02% |
4,234,218
+130,691
| +3% | +$7.89M |
|
484
Denali Therapeutics
DNLI
$4.04B
| $240M | 0.02% |
4,757,965
-145,487
| -3% | -$8.2M |
|
485
Campbell Soup
CPB
$6.74B
| $240M | 0.02% |
5,728,571
+264,741
| +5% | +$11.5M |
|
|
EQC
486
DELISTED
Equity Commonwealth
EQC
| $239M | 0.02% |
9,199,824
+5,407,361
| +143% | +$142M |
|
|
PPBI
487
DELISTED
Pacific Premier Bancorp
PPBI
| $237M | 0.02% |
5,717,268
-94,034
| -2% | -$3.69M |
|
488
RTX Corp
RTX
$300B
| $235M | 0.02% |
2,738,049
+253,006
| +10% | +$21.6M |
|
489
Diamondback Energy
FANG
$56.2B
| $235M | 0.02% |
2,482,064
-42,021
| -2% | -$3.38M |
|
490
Darling Ingredients
DAR
$10B
| $235M | 0.02% |
3,265,873
+428,748
| +15% | +$30.7M |
|
|
JBGS
491
JBG SMITH
JBGS
$691M
| $235M | 0.02% |
7,923,346
-825,248
| -9% | -$25.5M |
|
492
Fate Therapeutics
FATE
$317M
| $235M | 0.02% |
3,956,495
+846,663
| +27% | +$66.4M |
|
493
PROG Holdings
PRG
$1.64B
| $234M | 0.02% |
5,579,174
-28,435
| -0.5% | -$1.28M |
|
494
Belden
BDC
$5.39B
| $234M | 0.02% |
4,021,728
-116,709
| -3% | -$6.25M |
|
495
Reynolds Consumer Products
REYN
$5.53B
| $234M | 0.02% |
8,557,514
+558,713
| +7% | +$16M |
|
496
Southwest Gas
SWX
$6.68B
| $233M | 0.02% |
3,483,498
+270,078
| +8% | +$18.8M |
|
497
Reliance Steel & Aluminium
RS
$21.8B
| $233M | 0.02% |
1,635,294
+17,251
| +1% | +$2.59M |
|
|
PXD
498
DELISTED
Pioneer Natural Resource Co.
PXD
| $232M | 0.02% |
1,395,103
-647,432
| -32% | -$98M |
|
499
SPX Corp
SPXC
$10.9B
| $231M | 0.02% |
4,325,393
+62,929
| +1% | +$3.86M |
|
500
Bristol-Myers Squibb
BMY
$130B
| $231M | 0.02% |
3,899,199
+325,660
| +9% | +$21.4M |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.